Kodiak Sciences Inc (Nasdaq:KOD), a precommercial retina-focused biotechnology company, said on Friday that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the treatment of patients with wet age-related macular degeneration (AMD), on Monday, 28 September 2026.
The webcast can be accessed at https://edge.media-server.com/mmc/p/zcpk35f6/ or from the Events and Presentations page on Kodiak's website at https://ir.kodiak.com/events-and-presentations/events.
An archived replay of the webcast will be available for a limited time.
AstraZeneca's IMFINZI combination receives US Priority Review for muscle-invasive bladder cancer
Novotech to acquire Agilex Biolabs from Healius
ACROBiosystems launches CHO-Direct and ACRO AIx to accelerate AI-driven drug discovery
UChicago Medicine completes construction phase of new cancer facility
Viking Therapeutics plans offerings of common stock and convertible senior notes
Astellas doses first patient in Phase 3 lung cancer study
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Ondine Biomedical deployssteriwave across five Southern Ontario hospitals
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
AstronauTx receives funding to explore sleep-based approaches for Parkinson's disease
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Genentech reports positive Phase II results for enicepatide in type 2 diabetes